

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

June 14, 2001

General sheets if necessary)

ATTORNEY DOCKET NO.
1036.2001-006APPLICATION NO.
09/738,625APPLICANT
Arnold GlazierFILING DATE
December 15, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
KAC	5,849,718	12-15-98	Grosveld	514	44	
AB	5,820,847	10-13-98	Low, et al.	424	9.1	
AC	5,108,921	4-28-92	Low, et al.	435	240.1	
AD	5,416,016	5-16-95	Low, et al.	435	240.1	
AE	5,902,588	5-11-99	Greenwald, et al.	424	278.1	
AF	5,556,609	9-17-96	Zamora	424	1.69	
AG	5,567,408	10-22-96	Zamora	424	1.69	
AH	4,975,278	12-4-90	Senter, et al.	424	94.3	
AI	5,688,488	11-18-97	Low, et al.	424	1.69	
AJ	5,914,312	6-22-99	Axworthy, et al.	514	8	
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	WO 99/53951	28.10.99	PCT	A61K	39/385	
AM						
AN						
AO						
AP						
AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AR	Asayama, S., et al., "Comb-Type Prepolymers Consisting of a Polyacrylamide Backbone and Poly(L-lysine) Graft Chains for Multivalent Ligands," <i>Bioconjugate Chem.</i> , 10:246-253 (1999).
KAC	AS	Costa, T., et al., "Receptor Binding and Biological Activity of Bivalent Enkephalins," <i>Biochemical Pharmacology</i> , 34(1):25-30 (1985).
KAC	AT	Portoghese, P.S., et al., "Opioid Agonist and Antagonist Bivalent Ligands as Receptor Probes," <i>Life Sciences</i> , 31:1283-1286 (1982).

EXAMINER

DATE CONSIDERED

Karin A. Camilla

5/26/05

RECEIVED
OCT 02 2001
CH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

June 14, 2001

(See several sheets if necessary)

ATTORNEY DOCKET NO.
1036.2001-006APPLICATION NO.
09/738,625APPLICANT
Arnold GlazierFILING DATE
December 15, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAM INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	1	Portoghese, P. S., "Bivalent Ligands and the Message - Address Concept in the Design of Selective Opioid Receptor Antagonists," <i>TIPS</i> , 10:230-235 (1989).
AV	1	Crews, J.R., et al., "A Combination of Two Immunotoxins Exerts Synergistic Cytotoxic Activity Against Human Breast-Cancer Cell Lines," <i>Int. J. Cancer</i> , 51:772-779 (1992).
AW	1	Chari, R.V.J., "Targeted Delivery of Chemotherapeutics: Tumor-activated Prodrug Therapy," <i>Advanced Drug Delivery Reviews</i> , 31:89-104 (1998).
AX	1	Rihova, B. "Receptor-mediated Targeted Drug or Toxin Delivery," <i>Advanced Drug Delivery Reviews</i> , 29:273-289 (1998).
AY	1	Calas, M., et al., "Antimalarial Activity of Compounds Interfering with Plasmodium falciparum Phospholipid Metabolism: Comparison Between Mono- and Bisquaternary Ammonium Salts," <i>J. Med. Chem.</i> , 43:505-516 (2000).
AZ	1	Terskikh, A.V., et al., "'Peptabody': A New Type of High Avidity Binding Protein," <i>Proc. Natl. Acad. Sci.</i> 94:1663-1668 (1997).
AR2	1	Kohler, J., et al., "Cross-reactive Trinitrophenylated Peptides as Antigens for Class II Major Histocompatibility Complex-restricted T Cells and Inducers of Contact Sensitivity in Mice. Limited T Cell Receptor Repertoire," <i>Eur J Immunol</i> 25:92-101 (1995).
AS2	1	Sykulev, Y., et al., "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," <i>Immunity</i> 4:565-571 (1996).

EXAMINER

DATE CONSIDERED



5/26/05

RECEIVED
OCT 02 2001
FBI CENTER 1600/2900